Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yutaka Yasui
Observed name:
YUTAKA YASUI
Institution:
Musashino Red Cross Hospital
Observed institution:
Musashino Red Cross Hospital
ORCID:
0000-0002-6117-4990
Observed ORCID:
0000-0002-6117-4990
OpenAlex ID:
A5135582511
Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
2026
·
NAOKI UCHIHARA
, NOBUHARU TAMAKI
, et al.
·
Anticancer Research
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
2026
·
Chiaki Maeyashiki
, Nobuharu Tamaki
, et al.
·
Journal of Clinical Medicine
Clinical significance of neutrophil-to-lymphocyte ratio dynamics during cabozantinib therapy in unresectable hepatocellular carcinoma.
2026
·
Kaoru Tsuchiya
, Yutaka Yasui
, et al.
·
Journal of Clinical Oncology
Time-toxicity of first-line systemic therapy for hepatocellular carcinoma in clinical practice.
2026
·
Kenta Takaura
, Kaoru Tsuchiya
, et al.
·
Journal of Clinical Oncology
Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver Cirrhosis
2026
·
Yuki Tanaka
, Nobuharu Tamaki
, et al.
·
Nutrients
PDF
Show more works
View as search
Works count:
5
Citation count:
H-index:
I10-index:
Year
Topic
Type